Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out. Ongoing trials are assessing its efficacy for managing other cancers.
|
Read full article at Wikipedia
|
InChI=1S/C10H11ClFN5O3/c11- 10- 15- 7(13) 5- 8(16- 10) 17(2- 14- 5) 9- 4(12) 6(19) 3(1- 18) 20- 9/h2- 4,6,9,18- 19H,1H2,(H2,13,15,16) /t3- ,4+,6- ,9- /m1/s1 |
WDDPHFBMKLOVOX-AYQXTPAHSA-N |
Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F |
|
antimetabolite
A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine
|
clofarabina
|
ChEBI
|
clofarabine
|
KEGG DRUG
|
clofarabinum
|
ChEBI
|
(2R,3R,4S,5R)- 5- (6- amino- 2- chloropurin- 9- yl)- 4- fluoro- 2- (hydroxymethyl)oxolan- 3- ol
|
DrugBank
|
2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine
|
ChEBI
|
2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
|
ChemIDplus
|
CAFdA
|
ChEBI
|
Cl-F-Ara-A
|
ChEBI
|
clofarabine
|
ChEMBL
|
123318-82-1
|
CAS Registry Number
|
ChemIDplus
|
123318-82-1
|
CAS Registry Number
|
KEGG DRUG
|
4882539
|
Beilstein Registry Number
|
Beilstein
|
|